Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.84
REGN's Cash to Debt is ranked higher than
61% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. REGN: 1.84 )
REGN' s 10-Year Cash to Debt Range
Min: 0.57   Max: No Debt
Current: 1.84

Equity to Asset 0.68
REGN's Equity to Asset is ranked higher than
72% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.68 )
REGN' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.93
Current: 0.68

0.18
0.93
Interest Coverage 16.37
REGN's Interest Coverage is ranked higher than
55% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 16.37 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 16.37
Current: 16.37

0.46
16.37
F-Score: 4
Z-Score: 23.42
M-Score: -3.10
WACC vs ROIC
9.00%
18.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 30.56
REGN's Operating margin (%) is ranked higher than
95% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. REGN: 30.56 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 30.56

-554.63
187.97
Net-margin (%) 12.74
REGN's Net-margin (%) is ranked higher than
90% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. REGN: 12.74 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 12.74

-565.66
54.43
ROE (%) 15.53
REGN's ROE (%) is ranked higher than
94% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. REGN: 15.53 )
REGN' s 10-Year ROE (%) Range
Min: -75.77   Max: 86.68
Current: 15.53

-75.77
86.68
ROA (%) 10.43
REGN's ROA (%) is ranked higher than
94% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. REGN: 10.43 )
REGN' s 10-Year ROA (%) Range
Min: -28.05   Max: 44.08
Current: 10.43

-28.05
44.08
ROC (Joel Greenblatt) (%) 55.36
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. REGN: 55.36 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -214.91   Max: 168.03
Current: 55.36

-214.91
168.03
Revenue Growth (3Y)(%) 50.60
REGN's Revenue Growth (3Y)(%) is ranked higher than
98% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. REGN: 50.60 )
REGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.3   Max: 81.3
Current: 50.6

-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

REGN Guru Trades in Q1 2014

Paul Tudor Jones 893 sh (New)
Andreas Halvorsen 1,051,800 sh (New)
Ron Baron 6,084 sh (New)
Steven Cohen 65,232 sh (+130.47%)
Vanguard Health Care Fund 1,743,468 sh (+23.47%)
Frank Sands 4,012,062 sh (+7.48%)
Jim Simons Sold Out
» More
Q2 2014

REGN Guru Trades in Q2 2014

Jim Simons 2,862 sh (New)
Joel Greenblatt 881 sh (New)
Ray Dalio 18,400 sh (New)
Mario Gabelli 2,295 sh (New)
Andreas Halvorsen 2,963,456 sh (+181.75%)
Vanguard Health Care Fund 2,795,500 sh (+60.34%)
Frank Sands 4,907,362 sh (+22.32%)
Ron Baron 7,109 sh (+16.85%)
Steven Cohen 14,500 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2014

REGN Guru Trades in Q3 2014

Paul Tudor Jones 2,499 sh (New)
Ken Fisher 583 sh (New)
Jim Simons 26,562 sh (+828.09%)
Steven Cohen 23,600 sh (+62.76%)
Joel Greenblatt 1,410 sh (+60.05%)
Frank Sands 4,967,466 sh (+1.22%)
Ron Baron 7,109 sh (unchged)
Vanguard Health Care Fund 2,795,500 sh (unchged)
Mario Gabelli 2,190 sh (-4.58%)
Andreas Halvorsen 1,080,682 sh (-63.53%)
Ray Dalio 1,600 sh (-91.3%)
» More
Q4 2014

REGN Guru Trades in Q4 2014

Ray Dalio 11,800 sh (+637.5%)
Ron Baron 7,490 sh (+5.36%)
Vanguard Health Care Fund 2,921,000 sh (+4.49%)
Frank Sands 4,986,177 sh (+0.38%)
Mario Gabelli 2,190 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 524 sh (-10.12%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-12-31 Sold Out 1.6%$328.07 - $434.95 $ 413.045%0
Vanguard Health Care Fund 2014-12-31 Add 4.49%0.12%$328.07 - $434.95 $ 413.045%2921000
Ray Dalio 2014-12-31 Add 637.5%0.03%$328.07 - $434.95 $ 413.045%11800
Joel Greenblatt 2014-12-31 Sold Out 0.01%$328.07 - $434.95 $ 413.045%0
Andreas Halvorsen 2014-09-30 Reduce -63.53%2.35%$296.41 - $364.41 $ 413.0423%1080682
Ray Dalio 2014-09-30 Reduce -91.3%0.04%$296.41 - $364.41 $ 413.0423%1600
Joel Greenblatt 2014-09-30 Add 60.05%$296.41 - $364.41 $ 413.0423%1410
Ken Fisher 2014-09-30 New Buy$296.41 - $364.41 $ 413.0423%583
Andreas Halvorsen 2014-06-30 Add 181.75%2.39%$277.29 - $313.74 $ 413.0439%2963456
Vanguard Health Care Fund 2014-06-30 Add 60.34%0.79%$277.29 - $313.74 $ 413.0439%2795500
Frank Sands 2014-06-30 Add 22.32%0.64%$277.29 - $313.74 $ 413.0439%4907362
Ray Dalio 2014-06-30 New Buy0.04%$277.29 - $313.74 $ 413.0439%18400
Joel Greenblatt 2014-06-30 New Buy$277.29 - $313.74 $ 413.0439%881
Mario Gabelli 2014-06-30 New Buy$277.29 - $313.74 $ 413.0439%2295
Andreas Halvorsen 2014-03-31 New Buy1.3%$267.62 - $347.62 $ 413.0434%1051800
Vanguard Health Care Fund 2014-03-31 Add 23.47%0.29%$267.62 - $347.62 $ 413.0435%1743468
Frank Sands 2014-03-31 Add 7.48%0.22%$267.62 - $347.62 $ 413.0434%4012062
Ron Baron 2014-03-31 New Buy0.01%$267.62 - $347.62 $ 413.0434%6084
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 134.20
REGN's P/E(ttm) is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 134.20 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 138.89
Current: 134.2

9.83
138.89
Forward P/E 34.72
REGN's Forward P/E is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 34.72 )
N/A
PE(NRI) 134.80
REGN's PE(NRI) is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 134.80 )
REGN' s 10-Year PE(NRI) Range
Min: 10.65   Max: 139.75
Current: 134.8

10.65
139.75
P/B 16.50
REGN's P/B is ranked higher than
61% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. REGN: 16.50 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 16.5

1.43
26.42
P/S 17.40
REGN's P/S is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. REGN: 17.40 )
REGN' s 10-Year P/S Range
Min: 2.06   Max: 27.97
Current: 17.4

2.06
27.97
PFCF 82.90
REGN's PFCF is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 82.90 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 82.9

9.29
2102
POCF 54.49
REGN's POCF is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 54.49 )
REGN' s 10-Year POCF Range
Min: 7.52   Max: 359.87
Current: 54.49

7.52
359.87
EV-to-EBIT 51.98
REGN's EV-to-EBIT is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 51.98 )
REGN' s 10-Year EV-to-EBIT Range
Min: -106.3   Max: 2827.2
Current: 51.98

-106.3
2827.2
Shiller P/E 348.00
REGN's Shiller P/E is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 348.00 )
REGN' s 10-Year Shiller P/E Range
Min: 271.85   Max: 1446.63
Current: 348

271.85
1446.63
Current Ratio 5.36
REGN's Current Ratio is ranked higher than
68% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. REGN: 5.36 )
REGN' s 10-Year Current Ratio Range
Min: 2.17   Max: 20.69
Current: 5.36

2.17
20.69
Quick Ratio 5.07
REGN's Quick Ratio is ranked higher than
69% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. REGN: 5.07 )
REGN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 20.5
Current: 5.07

2.17
20.5
Days Inventory 145.92
REGN's Days Inventory is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 145.92 )
REGN' s 10-Year Days Inventory Range
Min: 61.88   Max: 432.93
Current: 145.92

61.88
432.93
Days Sales Outstanding 93.61
REGN's Days Sales Outstanding is ranked higher than
76% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. REGN: 93.61 )
REGN' s 10-Year Days Sales Outstanding Range
Min: 6.35   Max: 201.38
Current: 93.61

6.35
201.38

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 100.50
REGN's Price/Net Current Asset Value is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. REGN: 100.50 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.18   Max: 256.27
Current: 100.5

3.18
256.27
Price/Tangible Book 16.50
REGN's Price/Tangible Book is ranked higher than
66% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. REGN: 16.50 )
REGN' s 10-Year Price/Tangible Book Range
Min: 1.73   Max: 16.53
Current: 16.5

1.73
16.53
Price/DCF (Projected) 18.90
REGN's Price/DCF (Projected) is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 18.90 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 240.67
Current: 18.9

14.99
240.67
Price/Median PS Value 1.60
REGN's Price/Median PS Value is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. REGN: 1.60 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.03
Current: 1.6

0.21
5.03
Price/Graham Number 9.60
REGN's Price/Graham Number is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 9.60 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 8.4
Current: 9.6

1.24
8.4
Earnings Yield (Greenblatt) 1.90
REGN's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. REGN: 1.90 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 1.9

1.3
24.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:REGN.Switzerland,
Regeneron Pharmaceuticals Inc was incorporated in January 1988 in the State of New York. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
1 Feb 23 2015 
1 Feb 23 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 
Weekly Top Insider Sells: REGN May 27 2013 


More From Other Websites
Cramer's guide: Best stocks in a bearish market Mar 04 2015
Novartis treatment for vision loss meets goals in study Feb 27 2015
The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Feb 27 2015
Up and Down the Ladder: The Latest Comings & Goings at Alkermes, Charles River Labs and… Feb 27 2015
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 27 2015
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
Lightning Round: This group goes higher tomorrow Feb 25 2015
Cramer Remix: Where's the Nasdaq bubble? Feb 23 2015
Cramer: Watch out - regulators are gunning for these stoc... Feb 23 2015
Lightning Round: Don't listen to this CEO Feb 23 2015
Regeneron Shares Reach Full Valuation Feb 23 2015
Lightning Round: This stock's got to get game back Feb 20 2015
FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Feb 20 2015
Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Feb 19 2015
Update: Regeneron: Too Much Excitement About Eylea News? Feb 19 2015
Regeneron Pharms downgraded by ROTH Capital Feb 19 2015
REGENERON PHARMACEUTICALS INC Financials Feb 19 2015
Regeneron Tops Roche in Eye Drug Study That May Boost Sales Feb 19 2015
Regeneron: Need fair drug prices Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK